Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiac Science Inc. DFIB (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Marc Phelan who wrote (74)	3/28/2002 4:04:47 PM
From: Skywatcher	Respond to of 174

I think at $3 this is a good play even for another big runup.....product is good and they just sued over patent infringement as their big competitor is coming into the market with FDA approval. But that doesn't mean they didn't steal parts and ideas.... More and more organizations, locations, and schools are going to continue to purchase these units for the next several years. They don't cost as much as INVN type stuff.....but the market is astonomically bigger. I don't see any short covering playing a meaningful role in a runup....it's dropped by 70% since Jan so that card has been played....see chart! CC

To: Marc Phelan who wrote (74)	4/10/2002 12:56:47 PM
From: Skywatcher	Read Replies (1) \| Respond to of 174

Getting Europe on board and it's low today: Cardiac Science Selected to Supply Automated External Defibrillators (AEDs) In European Public Access Defibrillation ProgramDutch Government Passes Legislation Allowing Use of AEDs by Lay People - Cardiac Science and City of Maastricht, Netherlands Launch First PAD Program of Its Kind on the European Continent IRVINE, Calif., Apr 10, 2002 /PRNewswireFirstCall via COMTEX/ Cardiac Science, Inc. (Nasdaq: DFIB), a leading developer and manufacturer of lifesaving, automated public access defibrillators (AEDs), today announced that it has been selected to outfit the city of Maastricht, Netherlands, with its new Powerheart(R) AEDs as part of the Netherlands first municipal public access defibrillation program. In conjunction with this initiative, the Dutch Government has amended national legislation, allowing automated external defibrillators to be operated by lay people in an emergency. The Maastricht program, a collaboration of the Public Health Institute, Maastricht University, and the Maastricht University Hospital, has set out to deploy AEDs in all public places in the region where at least one sudden cardiac arrest per year has occurred and are targeting to increase the survival rates of victims of sudden cardiac arrest in the region from its current level of 7 percent to 25 percent. AEDs are easytouse automated devices designed to quickly and easily provide a lifesaving electric defibrillation shock to restore normal heart rhythm to a sudden cardiac arrest victim. AEDs have historically been used by first responders such as police, fire and ambulance personnel, and now are being deployed for use by the public at places where people gather, play and work. Dr. Johannes de Munter, M.D., Msc., of the Public Health Institute Maastricht, and Program Director for the Maastricht PAD program stated, "I am extremely satisfied with our selection of the Powerheart AED for our public access project in the Netherlands. We selected it based on its ease of use and the sophisticated manner in which it makes clinical determinations, allowing lay persons, even without prior training, to safely administer lifesaving care to a victim of cardiac arrest." Cardiac Science President and CEO Raymond W. Cohen said, "While the laws in many European and Asian countries are just beginning to allow use of AEDs by nonmedical persons, the demand for AEDs is expanding rapidly in the international markets. We continue to look for ways to develop creative and innovative partnerships with municipalities and distribution partners in America, as well in Europe. Recent announcements such as our alliance with Nihon Kohden in Japan, Complient Corporation and municipal partnerships such as Project Heart Beat in San Diego and the Maastricht program are testament to these efforts. With a solid worldwide distribution network in place for Europe, Asia, the Middle East and South America, Cardiac Science is experiencing significant international revenue growth. Sales to date in 2002 for the international market segment have exceeded $3 million which is more than Cardiac Science posted in total 2001 international revenue." CC